A method of modulating KSP kinesin activity in vitro comprising contacting KSP kinesin with at least one chemical entity chosen from compounds represented by Formula I: ##STR00001## and pharmaceutically acceptable salts thereof, where the variables are as defined further herein.

 
Web www.patentalert.com

< Preventing airway mucus production by administration of EGF-R antagonists

> Thiol terminated monodisperse ethylene oxide oligomer capped gold nanoclusters
~ 00413